391 related articles for article (PubMed ID: 26714009)
1. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study.
Amarenco G; Sutory M; Zachoval R; Agarwal M; Del Popolo G; Tretter R; Compion G; De Ridder D
Neurourol Urodyn; 2017 Feb; 36(2):414-421. PubMed ID: 26714009
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport® (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): A randomised placebo-controlled phase IIa study.
Denys P; Del Popolo G; Amarenco G; Karsenty G; Le Berre P; Padrazzi B; Picaut P;
Neurourol Urodyn; 2017 Feb; 36(2):457-462. PubMed ID: 26756554
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
[TBL] [Abstract][Full Text] [Related]
4. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
Rovner E; Dmochowski R; Chapple C; Thompson C; Lam W; Haag-Molkenteller C
Neurourol Urodyn; 2013 Nov; 32(8):1109-15. PubMed ID: 23389824
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies.
Franco I; Hoebeke P; Baka-Ostrowska M; Bolong D; Davies LN; Dahler E; Snijder R; Stroosma O; Verheggen F; Newgreen D; Bosman B; Vande Walle J
J Pediatr Urol; 2020 Apr; 16(2):180.e1-180.e8. PubMed ID: 32007426
[TBL] [Abstract][Full Text] [Related]
6. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
[TBL] [Abstract][Full Text] [Related]
7. A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction.
Welk B; Hickling D; McKibbon M; Radomski S; Ethans K
Neurourol Urodyn; 2018 Nov; 37(8):2810-2817. PubMed ID: 30168626
[TBL] [Abstract][Full Text] [Related]
8. Bladder wall thickness in women with symptoms of overactive bladder and detrusor overactivity: Results from the randomised, placebo-controlled shrink study.
Robinson D; Oelke M; Khullar V; Wijkstra H; Tretter R; Stow B; Compion G; Tubaro A
Neurourol Urodyn; 2016 Sep; 35(7):819-25. PubMed ID: 26199198
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).
Drake MJ; Chapple C; Esen AA; Athanasiou S; Cambronero J; Mitcheson D; Herschorn S; Saleem T; Huang M; Siddiqui E; Stölzel M; Herholdt C; MacDiarmid S;
Eur Urol; 2016 Jul; 70(1):136-145. PubMed ID: 26965560
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-Prospective, randomized, double-blind, placebo-controlled study.
Krhut J; Borovička V; Bílková K; Sýkora R; Míka D; Mokriš J; Zachoval R
Neurourol Urodyn; 2018 Sep; 37(7):2226-2233. PubMed ID: 29603781
[TBL] [Abstract][Full Text] [Related]
11. The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Naïve Patients with Refractory Overactive Bladder: Results from a Multicenter, Randomized, Double-Blind Phase 3b Trial.
Herschorn S; Kohan A; Aliotta P; McCammon K; Sriram R; Abrams S; Lam W; Everaert K
J Urol; 2017 Jul; 198(1):167-175. PubMed ID: 28161352
[TBL] [Abstract][Full Text] [Related]
12. AbobotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity regardless of spinal cord injury or multiple sclerosis etiology: Pooled analysis of two phase III randomized studies (CONTENT1 and CONTENT2).
Denys P; Castaño Botero JC; Vita Nunes RL; Wachs B; Mendes Gomes C; Krivoborodov G; Tu LM; Del-Popolo G; Thompson C; Vilain C; Volteau M; Kennelly M;
Neurourol Urodyn; 2023 Jan; 42(1):153-167. PubMed ID: 36321799
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
[TBL] [Abstract][Full Text] [Related]
14. OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology.
Ginsberg D; Cruz F; Herschorn S; Gousse A; Keppenne V; Aliotta P; Sievert KD; Brin MF; Jenkins B; Thompson C; Lam W; Heesakkers J; Haag-Molkenteller C
Adv Ther; 2013 Sep; 30(9):819-33. PubMed ID: 24072665
[TBL] [Abstract][Full Text] [Related]
15. Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis.
Madhuvrata P; Singh M; Hasafa Z; Abdel-Fattah M
Eur Urol; 2012 Nov; 62(5):816-30. PubMed ID: 22397851
[TBL] [Abstract][Full Text] [Related]
16. Combined antimuscarinics for treatment of neurogenic overactive bladder.
Nardulli R; Losavio E; Ranieri M; Fiore P; Megna G; Bellomo RG; Cristella G; Megna M
Int J Immunopathol Pharmacol; 2012; 25(1 Suppl):35S-41S. PubMed ID: 22652160
[TBL] [Abstract][Full Text] [Related]
17. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity.
Sussman D; Patel V; Del Popolo G; Lam W; Globe D; Pommerville P
Neurourol Urodyn; 2013 Mar; 32(3):242-9. PubMed ID: 22965657
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Gabapentin in Comparison to Solifenacin Succinate in Adult Overactive Bladder Treatment.
Chua ME; See MC; Esmeňa EB; Balingit JC; Morales ML
Low Urin Tract Symptoms; 2018 May; 10(2):135-142. PubMed ID: 28150436
[TBL] [Abstract][Full Text] [Related]
19. Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study.
Gibson W; MacDiarmid S; Huang M; Siddiqui E; Stölzel M; Choudhury N; Drake MJ
Eur Urol Focus; 2017 Dec; 3(6):629-638. PubMed ID: 28916436
[TBL] [Abstract][Full Text] [Related]
20. Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study.
Kitta T; Darekar A; Malhotra B; Shahin MH; Jones P; Lindsay M; Mallen S; Nieto A; Crook TJ
J Pediatr Urol; 2023 Apr; 19(2):175.e1-175.e10. PubMed ID: 36504158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]